Reckitt Benckiser Group eyes Pfizer unit
Published 07/12/2015 | 02:30
Reckitt Benckiser Group would consider acquiring Pfizer's consumer health unit were it to come up for sale in the wake of the Viagra maker's merger with Allergan. Buying the unit would add the Advil, ChapStick and Centrum brands to a fast-growing portfolio of consumer-health products such as Nurofen painkillers and Durex condoms, Reckitt's chief executive Rakesh Kapoor said.
Pfizer's €150bn merger with Allergan may lead to Pfizer splitting up the enlarged organisation, and the New York-based company has said it will decide on a potential separation by the end of 2018. "If the Pfizer consumer business was to come up for any number of reasons and if it goes through all these processes, would RB be interested to look at it? Yes," Mr Kapoor said.
An eventual disposal of the Pfizer unit is "inevitable," analysts at Exane BNP Paribas said last month.